Ductal Carcinoma in Situ (DCIS) News and Research

RSS
Ductal Carcinoma in Situ (DCIS) is a condition where the cells lining the milk ducts (the channels in the breast that carry milk to the nipple) are cancerous, but stay contained within the ducts without growing through into the surrounding breast tissue. DCIS may affect just one area of the breast, but can be more widespread and affect different areas at the same time. Sometimes DCIS may be described as pre-cancerous, pre-invasive, non-invasive, or intraductal cancer.
PINC trial to test anti-malarial drug in women with DCIS

PINC trial to test anti-malarial drug in women with DCIS

Women with low levels of income are susceptible to anxiety and depression after diagnosed with DCIS

Women with low levels of income are susceptible to anxiety and depression after diagnosed with DCIS

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Occult lesions identified with BSGI can be localized using multi-modality imaging for needle biopsy

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

BSGI proves to be an effective adjunct imaging modality for detecting DCIS

BSGI proves to be an effective adjunct imaging modality for detecting DCIS

NIH calls for identifying better methods to predict the risk of developing breast cancer

NIH calls for identifying better methods to predict the risk of developing breast cancer

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

Molecular mechanism responsible for transition of non-invasive breast cancer into invasive disease discovered

HER2/neu protein predicts development of invasive breast cancer in women with ductal carcinoma in situ

HER2/neu protein predicts development of invasive breast cancer in women with ductal carcinoma in situ

Loss of stromal protein major new prognostic factor in patients with breast cancer

Loss of stromal protein major new prognostic factor in patients with breast cancer

New DEAR1 gene predicts local recurrence in early-onset breast cancer

New DEAR1 gene predicts local recurrence in early-onset breast cancer

More women with early-stage breast cancer opting for double mastectomies

More women with early-stage breast cancer opting for double mastectomies

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

AVEO Pharmaceuticals announces findings from novel human-in-mouse cancer model system

Positron emission mammography effective in detecting breast cancer

Positron emission mammography effective in detecting breast cancer

Breast cancer increases with radiation delays

Breast cancer increases with radiation delays

Power3 Medical files two patent applications for breast cancer blood test

Power3 Medical files two patent applications for breast cancer blood test

Cells lining milk ducts hold key to spread of ductal carcinoma in situ

Cells lining milk ducts hold key to spread of ductal carcinoma in situ

MRI's high false positive rate has little impact on women's choice of preventive mastectomy

MRI's high false positive rate has little impact on women's choice of preventive mastectomy

Ductal carcinoma in situ patients overestimate breast cancer risks

Ductal carcinoma in situ patients overestimate breast cancer risks

American women prefer overly aggressive treatments for breast cancer

American women prefer overly aggressive treatments for breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.